So this looked at patients with ER-positive, HER2-Positive metastatic breast cancer who had received induction chemotherapy ...
In this analysis of the phase 3 ALLTO trial, researchers explored 10-year outcomes of HR+, HER2+ early breast cancer patients who received either an aromatase inhibitor or a selective estrogen ...
In March 2025, The FDA awarded orphan drug designation to Nerlynx® (neratinib) for treating breast cancer patients with brain ...
The presence of circulating tumor DNA (ctDNA) in patients with human epidermal growth factor receptor 2 (HER2)-positive ...
Timely initiation of targeted therapy is crucial for improving cancer outcomes and patient quality of life, especially for ...
Forget about Herceptin. There’s a new HER2 agent that ought to be used in HER2-positive stomach cancer, and that’s Jazz ...
Phase 1b study to evaluate combination of zongertinib and zanidatamab in HER2-positive breast cancer patients Ingelheim, Germany– 12 January, ...
Detailed price information for Abpro Holdings Inc (ABP-Q) from The Globe and Mail including charting and trades.
HER2CLIMB-05 trial evaluated Tukysa in combination with Herceptin and Perjeta for HER2-positive metastatic breast cancer, ...
Trastuzumab-based regimens were the primary treatment for older adults with advanced HER2-positive gastric cancer before immunotherapy became standard. The study highlights substantial economic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback